Antibiotic Treatment foLlowing Surgical drAinage of Perianal abScess; the ATLAS Trial

Not Applicable

Recruiting

• Conditions: Perianal Fistula; Drain Abscess; Perianal Abscess
• Interventions: Drug: Ciprofloxacin 500 mg; Drug: Placebo; Drug: Metronidazole 500 mg

• Registration Number: NCT05385887
• Lead Sponsor: dr. IJM Han-Geurts

Brief Summary

Rationale:

Perianal fistula is a burdening disease with an annual prevalence of 2/100.000 in the Dutch population. More than 90% of crypto-glandular fistulas originate from anorectal abscess. Despite adequate drainage of anorectal abscess up to 83% recurs or results in an anal fistula, the majority developing within 12 months. Up till now it is not common practice to routinely administer prophylactic antibiotics to prevent anal fistula development.\\

Objective:

The objective of this trial is to establish if adding antibiotic treatment to surgical drainage of perianal abscess results in less perianal fistulas.

Study design:

The study concerns a double-blind, placebo-controlled, randomized, multicenter trial with treatment of perianal abscess by surgical drainage alone or combined with antibiotic treatment. Patients will be accrued by all participating clinics. The design involves allocation of all appropriate consecutive patients with a primary occurrence of perianal abscess to surgical drainage followed by either antibiotics or placebo. Data will be analyzed on 'intention to treat' basis in case patients are not subjected to the randomized treatment modality.

Study population:

Men and women of 18 years and older who present for the first time with a perianal abscess.

Intervention (if applicable): The antibiotic group receives 7 days of oral metronidazole (500 mg every eight hours) and ciprofloxacin (500 mg every twelve hours) in addition to surgical drainage. The other group receives surgical drainage and postoperatively identical placebo tablets.

Main study parameters/endpoints:

Primary outcome measure is development of a perianal fistula. Secondary outcome measures are quality of life at 12 months measured with the EQ-5D-5L with Dutch rating. Further: in-hospital direct and indirect costs and out-of hospital postoperative costs, need of repeated drainage, patient related outcome (PRO) and clinical outcome measures.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

For this study, patients are asked to take part in a study comparing the addition of antibiotic treatment to surgical drainage of perianal abscess. Patients will not be burdened by extra hospital visits. At baseline participants will complete PRO questionnaires. Also at 1 week and 3, 6 and 12 months participants will fulfill the PRO questionnaires. These will be send to them by email and will take approximately 10 minutes each time.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-12-23
• Study First Submitted: 2022-05-12
• Study First Submitted QC: 2022-05-17
• Study First Posted: 2022-05-23
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-10
• Last Update Posted: 2023-11-13
• Primary Completion: 2024-12-31
• Study Completion: 2025-08-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 298

Inclusion Criteria

• Men and women aged 18 years or older
• Eligible for e-mail questionnaires
• Sufficient understanding of the Dutch written language (reading and writing)
• Obtained written informed consent

Exclusion Criteria

• A coexistent anorectal fistula

• Secondary or recurrent anorectal abscess

• Presence of an internal fistula opening

• Any additional surgical procedure performed during the same session

• Previous (peri)anal surgery

• Inflammatory bowel disease

• History of radiation of the pelvic area

• Anorectal malignancy

• Immunodeficiency

• Kidney failure (eGFR <30ml/min)

• Valvular heart disease

• Pregnancy or lactation

• Postoperative antibiotic prophylaxis indicated for another reason

• Immunosuppressive medication at the time of surgery

• Allergy to metronidazole or ciprofloxacin

• Not able or trouble with swallowing pills

• Concomitant use of:

  • Tizanidine, theophylline, clozapine, olanzapine, pirfenidone, carbamazepine, agomelatine (these are all CYP1A2 substrates, ciprofloxacin is an inhibitor)
  • Amiodarone, erythromycin, sotalol, azithromycin, citalopram, escitalopram, flecainide, fluconazole, haloperidol >5mg/day, methadone, ondansetron (concerning prolonged QT interval in combination with ciprofloxacin)
  • Lithium (can cause toxic levels with metronidazole)
  • Lopinavir/ritonavir, ritonavir capsules, temsirolimus, disulfiram (antabuse), mebendazole (can cause serious side effects, confusion and psychosis in combination with metronidazole)
  • Corticosteroids (in combination with ciprofloxacin higher risk of tendinitis and tendon rupture).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Antibiotic treatment	Ciprofloxacin 500 mg	Two kinds of antibiotics: Ciprofloxacine 500mg 2dd \& Metronidazole 500mg 3dd
Antibiotic treatment	Metronidazole 500 mg	Two kinds of antibiotics: Ciprofloxacine 500mg 2dd \& Metronidazole 500mg 3dd
Placebo	Placebo	Placebo tabletes

Primary Outcome Measures

Name	Time	Method
Perianal fistula at 1 year follow up	1 year	A perianal fistula is diagnosed based on findings from physical examination or by a telephone call after 12 months were the doctor asks for symptoms as serosanguinous discharge and pain. An external opening with or without serosanguilent discharge is considered a fistula. In case of doubt an endoanal ultrasonography or MRI is performed.; So: yes/no fistula (dichotomous parameter)

Secondary Outcome Measures

Name	Time	Method
Need of repeated drainage	1 year
PROMs	1 year	Patient related outcome (PRO) are complaint reduction assessed by a proctology specific validated patient-related outcome measure, the proctoPROM(14). This was recently developed and validated at Proctos Clinic. At baseline participants will complete PRO questionnaires. Also at 1 week and 3, 6 and 12 months participants will fulfill the PRO questionnaires. These will be send to them by email with access to a web tool (Castor). If the patient does not have an email account, the questionnaires will be send the patients' home address, accompanied by a return envelope provided with postage stamps and the address of the hospital.
Recurrent abscess	1 year	(Recurrent) abscess within one year. Yes/no (dichotomous)
Quality of life at 12 months measured with the EQ-5D-5L with Dutch rating.	1 year	The EQ-5D-5L is a generic Health Related Quality of Life (HRQoL) measure, which is broadly used in economic evaluation. The instrument examines a patient's HRQoL on the day of the interview. It consists of the EQ-5D-5L descriptive system and the EQ-Visual Analogue Scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has five levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses to the 5 items result in a patient's health state that can be transformed into an index score representing health-related quality of life, ranging between 0 (death) and 1 (full health). These index scores are combined with length of life to calculate the QALY. The EQ-VAS records the patient's self-rated health with endpoints labelled 'the best health you can imagine' at the top and 'the worst health you can imagine' at the bottom.
In-hospital direct and indirect costs and out-of hospital posteroperative costs	1 year	In-hospital direct and indirect costs (measured with iPCQ and iMCQ) and out-of hospital postoperative costs.
Day of discharge from hospital	1 year	Day of discharge from hospital;
Duration of absence from work	1 year	Duration of absence from work. Amound of days is recorded (continuous scale)
Postoperative complications	1 year	Complications (postoperative bleeding, urinary retention requiring catheterisation, emergency reoperation, anal stenosis and fecal incontinence) including death and cause of death within 30 days will be reported using the Clavien-Dindo classification of surgical complications(15).

Trial Locations

Locations (11)

Rode Kruis ziekenhuis; 🇳🇱 Beverwijk, Noord-Holland, Netherlands

Dijklander hospital; 🇳🇱 Hoorn, North-Holland, Netherlands

Proctos kliniek; 🇳🇱 Bilthoven, Utrecht, Netherlands

Elisabeth-TweeSteden ziekenhuis; 🇳🇱 Tilburg, Noord-Brabant, Netherlands

Amphia hospital; 🇳🇱 Breda, North-Brabant, Netherlands

OLVG; 🇳🇱 Amsterdam, North-Holland, Netherlands

Albert Schweitzer ziekenhuis; 🇳🇱 Dordrecht, Zuid-Holland, Netherlands

Flevoziekenhuis; 🇳🇱 Almere, Netherlands

University Medical Center location AMC; 🇳🇱 Amsterdam, Netherlands

IJsselland ziekenhuis; 🇳🇱 Capelle Aan Den IJssel, Netherlands

Diakonessenhuis; 🇳🇱 Utrecht, Netherlands